Trial Profile
A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs NLG 802 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors NewLink Genetics Corporation
- 03 Jun 2020 Status changed from active, no longer recruiting to completed.
- 23 May 2019 According to a NewLink Genetics Corporation media release, data from the study were presented at the Immuno-Oncology 2019 2nd World Congress.
- 23 May 2019 Results presented in a NewLink Genetics Corporation media release.